New Trends and Therapies for Familial Hypercholesterolemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36431115/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions/Relevance: Newer therapies such as inhibitors of microsomal transfer protein and angiopoietin-like protein 3 have opened the possibility of LDL-cholesterol normalization in homozygous FH and may provide an alternative to lipoprotein apheresis for these patients. Gene-based therapies may provide more definite solutions for lowering...
Share
Genome Editing in Dyslipidemia and Atherosclerosis
Source : https://link.springer.com/chapter/10.1007/978-981-19-5642-3_10
Hardcover Book USD 199.99 Price excludes VAT (USA) We acknowledge the Servier Medical Art for providing basic graph elements for our figures, PubMed for publication statistics, and NHGRI-EBI GWAS Catalog...
Relevance: We give an outlook on the potential gene targets prioritized by large-scale genetic studies of cardiovascular diseases and genome editing in precision medicine of dyslipidemia and atherosclerosis.
Share
Familial Hypercholesterolemia and Its Current Diagnostics and Treatment Possibilities: A Literature Analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36422206/
Familial hypercholesterolemia (FH) is a common, inherited disorder of cholesterol metabolism. This pathology is usually an autosomal dominant disorder and is caused by inherited mutations in the APOB, LDLR, and...
Relevance: It is important to say that the timeous lowering of LDL-C levels can reduce the risk of cardiovascular events and mortality in patients with FH. Therefore, it is essential to increase awareness of FH in order to reduce the burden of acute coronary syndrome (ACS).
Share
Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan
Source : https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_63789/_article
Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is a powerful low density lipoprotein cholesterol (LDL-C)-lowering therapy, but this drug is expensive. This study aimed to describe the real-world treatment...
Conclusions: In the real-world practice in Taiwan, the LDL-C reduction efficacy of PCSK9 inhibitors was slightly lower than that reported in the clinical trials. The use of non-standard-dosing PCSK9 inhibitors was not uncommon in Taiwan.
Share
Recent Advances in Gene Therapy for Familial Hypercholesterolemia: An Update Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36431249/
(1) Background: Existing lipid-lowering therapies have difficulty in achieving lipid target levels in patients with familial hypercholesterolemia (FH), especially in the treatment of patients with homozygous familial hypercholesterolemia. (2) Method:...
Conclusion: Gene therapy is being widely used for the lipid-lowering treatment of FH patients and has shown excellent therapeutic promise, but the current delivery efficiency, economic burden, immunogenicity and the precision of gene therapy can be further optimized.
Share